Literature DB >> 34462876

Advancement of the Infant Air-Jet Dry Powder Inhaler (DPI): Evaluation of Different Positive-Pressure Air Sources and Flow Rates.

Connor Howe1, Mohammad A M Momin2, Dale R Farkas1, Serena Bonasera2, Michael Hindle2, P Worth Longest3,4.   

Abstract

PURPOSE: In order to improve the delivery of dry powder aerosol formulations to the lungs of infants, this study implemented an infant air-jet platform and explored the effects of different air sources, flow rates, and pulmonary mechanics on aerosolization performance and aerosol delivery through a preterm nose-throat (NT) in vitro model.
METHODS: The infant air-jet platform was actuated with a positive-pressure air source that delivered the aerosol and provided a full inhalation breath. Three different air sources were developed to provide highly controllable positive-pressure air actuations (using actuation volumes of ~10 mL for the preterm model). While providing different flow waveform shapes, the three air sources were calibrated to produce the same flow rate magnitude (Q90: 90th percentile of flow rate). Multiple air-jet DPI designs were coupled with the air sources and evaluated with a model spray-dried excipient enhanced growth formulation.
RESULTS: Compared to other designs, the D1-Single air-jet DPI provided improved performance with low variability across all three air sources. With the tested D1-Single air-jet and Timer air source, reducing the flow rate from 4 to 1.7 L/min marginally decreased the aerosol size and significantly increased the lung delivery efficiency above 50% of the loaded dose. These results were not impacted by the presence of downstream pulmonary mechanics (resistance and compliance model).
CONCLUSIONS: The selected design was capable of providing an estimated >50% lung delivery efficiency of a model spray-dried formulation and was not influenced by the air source, thereby enabling greater flexibility for platform deployment in different environments.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  high efficiency aerosolization; infant DPI; inline DPI; nose-to-lung aerosol delivery; positive pressure DPI; trans-nasal aerosol delivery

Mesh:

Substances:

Year:  2021        PMID: 34462876      PMCID: PMC8642819          DOI: 10.1007/s11095-021-03094-w

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  48 in total

1.  Characterization of Nanoaerosol Size Change During Enhanced Condensational Growth.

Authors:  P Worth Longest; James T McLeskey; Michael Hindle
Journal:  Aerosol Sci Technol       Date:  2010-06-01       Impact factor: 2.908

2.  High flow through a nasal cannula and CPAP effect in a simulated infant model.

Authors:  Teresa A Volsko; Kathy Fedor; Jason Amadei; Robert L Chatburn
Journal:  Respir Care       Date:  2011-06-17       Impact factor: 2.258

3.  Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia.

Authors:  T F Fok; S Monkman; M Dolovich; S Gray; G Coates; B Paes; F Rashid; M Newhouse; H Kirpalani
Journal:  Pediatr Pulmonol       Date:  1996-05

4.  Deposition studies of aerosol delivery by nasal cannula to infants.

Authors:  Timothy E Corcoran; Al Saville; Phillip S Adams; Darragh J Johnston; Michael R Czachowski; Yuliya A Domnina; Jiuann-Huey Lin; Daniel J Weiner; Alex S Huber; Joan Sanchez De Toledo; Cecilia W Lo
Journal:  Pediatr Pulmonol       Date:  2019-04-01

5.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

6.  Efficient Nose-to-Lung Aerosol Delivery with an Inline DPI Requiring Low Actuation Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2018-08-21       Impact factor: 4.200

7.  In Vitro Evaluation of Aerosols Delivered via the Nasal Route.

Authors:  Katia K El Taoum; Jinxiang Xi; JongWong Kim; Ariel Berlinski
Journal:  Respir Care       Date:  2015-01-13       Impact factor: 2.258

Review 8.  Aerosol therapy for children.

Authors:  B K Rubin; J B Fink
Journal:  Respir Care Clin N Am       Date:  2001-06

9.  Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device.

Authors:  Michael Hindle; P Worth Longest
Journal:  J Pharm Pharmacol       Date:  2012-02-21       Impact factor: 3.765

10.  Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler.

Authors:  Karl Bass; Dale Farkas; Worth Longest
Journal:  AAPS PharmSciTech       Date:  2019-11-01       Impact factor: 3.246

View more
  4 in total

1.  Characterizing the Effects of Nasal Prong Interfaces on Aerosol Deposition in a Preterm Infant Nasal Model.

Authors:  Karl Bass; Mohammad A M Momin; Connor Howe; Ghali Aladwani; Sarah Strickler; Arun V Kolanjiyil; Michael Hindle; Robert M DiBlasi; Worth Longest
Journal:  AAPS PharmSciTech       Date:  2022-04-19       Impact factor: 3.246

2.  Computational Fluid Dynamics (CFD) Guided Spray Drying Recommendations for Improved Aerosol Performance of a Small-Particle Antibiotic Formulation.

Authors:  Worth Longest; Amr Hassan; Dale Farkas; Michael Hindle
Journal:  Pharm Res       Date:  2022-02-11       Impact factor: 4.200

3.  In Vitro Analysis of Nasal Interface Options for High-Efficiency Aerosol Administration to Preterm Infants.

Authors:  Connor Howe; Mohammad A M Momin; Karl Bass; Ghali Aladwani; Serena Bonasera; Michael Hindle; Philip Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2022-02-14       Impact factor: 3.440

4.  Development of a High-Dose Infant Air-Jet Dry Powder Inhaler (DPI) with Passive Cyclic Loading of the Formulation.

Authors:  Connor Howe; Mohammad A M Momin; Ghali Aladwani; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2022-10-17       Impact factor: 4.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.